



**BlueCross
BlueShield**

Federal Employee Program.

Blue Cross Blue Shield Association
750 9th St NW, Suite 900
Washington, D.C. 20001
1-800-624-5060
Fax 1-877-378-4727

5.60.059

Section:	Prescription Drugs	Effective Date:	July 1, 2026
Subsection:	Central Nervous System Drugs	Original Policy Date:	June 2, 2023
Subject:	Lumryz	Page:	1 of 5

Last Review Date: June 11, 2026

Lumryz

Description

Lumryz (sodium oxybate)

Background

Lumryz (sodium oxybate) is a central nervous system depressant used for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy. The mechanism of action of Lumryz in the treatment of narcolepsy is unknown. Sodium oxybate is the sodium salt of gamma-hydroxybutyrate (GHB) an endogenous compound and metabolite of the neurotransmitter GABA. It is hypothesized that the therapeutic effects of Lumryz on cataplexy and excessive daytime sleepiness are mediated through GABA_B actions at noradrenergic and dopaminergic neurons, as well as at thalamocortical neurons (1).

Regulatory Status

FDA-approved indications: Lumryz is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy (1).

Lumryz includes a boxed warning citing the risks of central nervous system (CNS) depression and abuse and misuse. Use caution when considering the concurrent use of Lumryz with other CNS depressants. Because of the risks of CNS depression, abuse, and misuse Lumryz is available only through a restricted program called the Lumryz REMS (1).

Lumryz has warnings for depression and suicidality, confusion/anxiety, parasomnias, and high sodium content in Lumryz. In addition, patients should be instructed to not engage in activities

Section:	Prescription Drugs	Effective Date:	July 1, 2026
Subsection:	Central Nervous System Drugs	Original Policy Date:	June 2, 2023
Subject:	Lumryz	Page:	2 of 5

requiring mental alertness or motor coordination, including operating hazardous machinery, for at least 6 hours of dosing or after first initiating treatment until certain that Lumryz does not affect them adversely (1).

Lumryz is contraindicated in patients with succinic semialdehyde dehydrogenase deficiency and in combination with sedative hypnotics or alcohol (1).

Safety and effectiveness of Lumryz in patients less than 7 years of age have not been established (1).

Related policies

Hetlioz, Orexin Antagonists, Rozerem, Sedative Hypnotics, Xyrem, Xywav

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Lumryz may be considered **medically necessary** if the conditions indicated below are met.

Lumryz may be considered **investigational** for all other indications.

Prior-Approval Requirements

Age 7 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Cataplexy in narcolepsy
2. Excessive daytime sleepiness (EDS) in narcolepsy

AND ALL of the following:

1. Patient and prescriber are both enrolled in the Lumryz REMS Program
2. Prescriber will monitor for signs of misuse, abuse, and addiction during therapy

AND NONE of the following:

Section:	Prescription Drugs	Effective Date:	July 1, 2026
Subsection:	Central Nervous System Drugs	Original Policy Date:	June 2, 2023
Subject:	Lumryz	Page:	3 of 5

1. Succinic semialdehyde dehydrogenase deficiency
2. Concurrent therapy with a Prior Authorization (PA) sleep aid (see Appendix 1) or with another oxybate product (see Appendix 2)

Prior – Approval *Renewal* Requirements

Age 7 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Cataplexy in narcolepsy
2. Excessive daytime sleepiness (EDS) in narcolepsy

AND ALL of the following:

1. Prescriber will continue to monitor for signs of misuse, abuse, and addiction during therapy
2. **NO** concurrent therapy with another Prior Authorization (PA) sleep aid (see Appendix 1) or with another oxybate product (see Appendix 2)

Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Quantity 810 grams (90 packets) per 90 days

Duration 6 months

Prior – Approval *Renewal* Limits

Quantity 810 grams (90 packets) per 90 days

Duration 12 months

Section:	Prescription Drugs	Effective Date:	July 1, 2026
Subsection:	Central Nervous System Drugs	Original Policy Date:	June 2, 2023
Subject:	Lumryz	Page:	4 of 5

Rationale

Summary

Lumryz (sodium oxybate) is a central nervous system depressant used for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy. Lumryz includes a boxed warning citing the risks of central nervous system depression and abuse and misuse. Lumryz has warnings for depression and suicidality, confusion/anxiety, parasomnias, and high sodium content in Lumryz. Lumryz is available only through a restricted distribution program called the Lumryz REMS. Safety and effectiveness of Lumryz in patients less than 7 years of age have not been established (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Lumryz while maintaining optimal therapeutic outcomes.

References

1. Lumryz [package insert]. Chesterfield, MO: Avadel CNS Pharmaceuticals, LLC; December 2025.

Policy History

Date	Action
June 2023	Addition to PA
September 2023	Annual review
December 2023	Annual review
June 2024	Annual review
November 2024	Per PI update, reduced age requirement to 7 and older
December 2024	Annual review
June 2025	Annual review
June 2026	Annual review and reference update

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on June 11, 2026 and is effective on July 1, 2026.

Section:	Prescription Drugs	Effective Date:	July 1, 2026
Subsection:	Central Nervous System Drugs	Original Policy Date:	June 2, 2023
Subject:	Lumryz	Page:	5 of 5

Appendix 1 - List of Prior Authorization (PA) Sleep Aids

Generic Name	Brand Name
daridorexant	Quviviq
estazolam	Prosom
eszopiclone	Lunesta
flurazepam	Dalmane
lemborexant	Dayvigo
quazepam	Doral
ramelteon	Rozerem
tasimelteon	Hetlioz
suvorexant	Belsomra
temazepam	Restoril
triazolam	Halcion
zaleplon	Sonata
zolpidem	Ambien
zolpidem extended-release	Ambien CR
zolpidem oral spray	Zolpimist
zolpidem sublingual	Edluar
zolpidem sublingual	Intermezzo

Appendix 2 - List of Oxybate Products

Generic Name	Brand Name
sodium oxybate	Lumryz
sodium oxybate	Xyrem
calcium, magnesium, potassium, sodium oxybates	Xywav